{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:35:22Z","timestamp":1761863722614,"version":"3.37.3"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0176858","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T13:30:40Z","timestamp":1499434240000},"page":"e0176858","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of dasabuvir\/ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus in clinical practice: A population-based observational study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5797-0786","authenticated-orcid":true,"given":"Maya","family":"Leventer-Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Hammerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Brufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Hoshen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaffa","family":"Ashur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicky","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Balicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"P Andreone","year":"2014","journal-title":"Gastroenterology"},{"issue":"17","key":"ref2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-Ombitasvir and Dasabuvir with Ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"ref3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct-acting antiviral therapy for chronic hepatitis C","volume":"22","author":"JA Gutierrez","year":"2015","journal-title":"J Viral Hepat"},{"issue":"21","key":"ref5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"MS Sulkowski","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"e0145953","DOI":"10.1371\/journal.pone.0145953","article-title":"Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naive Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis","volume":"10","author":"T Suwanthawornkul","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"ref8","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-Ombitasvir and Dasabuvir with Ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/2040622315603642","article-title":"Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes","volume":"6","author":"JM Wilder","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"M Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s12325-015-0258-5","article-title":"Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)","volume":"32","author":"DR Walker","year":"2015","journal-title":"Adv Ther"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.7326\/M15-0642","article-title":"Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial","volume":"163","author":"A Kohli","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref13","article-title":"Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System","author":"GN Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"ref14","article-title":"A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease","author":"A Maruyama","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV\/HCV in the Real World?","volume":"62","author":"S Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/apt.13300","article-title":"Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans","volume":"42","author":"LI Backus","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir +\/- ribavirin vs. ombitasvir\/paritaprevir\/ritonavir + dasabuvir +\/- ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"LI Backus","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"Pt 3","key":"ref18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1017\/S1744133107004100","article-title":"Who switches sickness funds in Israel?","volume":"2","author":"A Shmueli","year":"2007","journal-title":"Health Econ Policy Law"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12963-014-0032-y","article-title":"Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel","volume":"12","author":"T Karpati","year":"2014","journal-title":"Popul Health Metr"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"M Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"ref22","unstructured":"Johns Hopkins University, Bloomberg School of Public Health. The Johns Hopkins ACG System: Version 11.0 Technical Reference Guide. 2014. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/cntrb_035024.pdf\" xlink:type=\"simple\">http:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/cntrb_035024.pdf<\/ext-link>. Accessed July 25, 2016."},{"issue":"7","key":"ref23","first-page":"458","article-title":"New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection","volume":"11","author":"AK Ara","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/17512433.2015.1086266","article-title":"Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?","volume":"8","author":"F Fabrizi","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1060028015570729","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection","volume":"49","author":"OM Klibanov","year":"2015","journal-title":"Ann Pharmacother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0176858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:04:49Z","timestamp":1540296289000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0176858"}},"subtitle":[],"editor":[{"given":"Ravi","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0176858","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,7,7]]}}}